Anna Karmann
Chief Medical Officer AdvanCell
Dr. Anna Karmann, MD, PhD, is the Chief Medical Officer at AdvanCell, a clinical-stage radiopharmaceutical company pioneering 212Pb-based Alpha Therapies. Dr. Karmann brings extensive expertise in molecular imaging, radiobiology, radiopharmaceutical therapies and drug development innovation. Prior to joining AdvanCell, she led early-stage asset development at RayzeBio and served as a management consultant at McKinsey & Company, focusing on clinical development, regulatory and operational excellence.
Dr. Karmann is a board-certified diagnostic and interventional Radiologist and holds an MD from RWTH Aachen University, a PhD from Maastricht University, and an MBA from RWTH Aachen University and Tsinghua University Beijing. She obtained significant clinical practice and research experience in Germany, the Netherlands and Stanford, US.
At the upcoming session on “Increasing R&D Productivity with Clinical Development Excellence,” Dr. Karmann will share insights from her extensive experience in the field.
Seminars
Serving as a bridge between preclinical and clinical development, phase zero studies can de-risk drug development by unlocking crucial pharmacokinetic and biodistribution data to optimize radiopharmaceutical drug candidates. Patient-centricity is at the core of phase zero studies and ethical considerations must be front and center in decision-making.
- Join this discussion-based workshop to gain insights on:
- Uncovering variations in compassionate use across countries like South Africa, Australia, Germany, and India, each with unique purposes and ethical considerations
- Ensuring ethical practices in diagnostics trials and patient involvement, advocating against unnecessary patient risk
- Guiding the design of Phase 1 trials by providing insights into optimal dosing, scheduling, and safety considerations
• Exploring global early-stage and late-stage development strategies
• Navigating patient selection and enrichment with imaging biomarkers; theranostic pair development
• Using biodistribution imaging and dosimetry while considering Ph1 study designs and dose optimization
